TARS Tarsus Pharmaceuticals, Inc.: Enterprise Value-to-Revenue Multiple

Official company branding of tarsusrx.com (TARS)

The prospects for Tarsus Pharmaceuticals (TARS) are expanding due to AI algorithms and the automation of drop synthesis, as confirmed by the EV/Sales multiple chart. The value 5289.70 reflects the current level of this metric. Business protection is ensured by patents and strict FDA control. The company's environmental strategy is based on the proper disposal of laboratory waste, minimizing its industrial footprint.

TARS: Tarsus Pharmaceuticals Enterprise Value-to-Revenue Ratio 11/23/2025 - 11/20/2026

Tarsus Pharmaceuticals Inc - analytical breakdowns and key metrics (TARS)

- market price and analyst price targets:
- company stock capitalization data:
Initial company analysis:tarsusrx.com TARS
Manufactured products of Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals (TARS) maintains a monopoly position in the blepharitis therapy market, and inelastic demand allows the company to exercise pricing power, which directly impacts its market capitalization. By analyzing the current enterprise value-to-revenue ratio, an investor assesses the business excluding debt and inflationary pressures; a decline in this multiple signals a risk of margin compression and a potential "value trap" for the asset.